Nuveen Asset Management LLC Has $4.35 Million Stake in InMode Ltd. (NASDAQ:INMD)

Nuveen Asset Management LLC decreased its stake in InMode Ltd. (NASDAQ:INMD - Free Report) by 7.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,280 shares of the healthcare company's stock after selling 19,702 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.37% of InMode worth $4,347,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of INMD. Barclays PLC grew its holdings in InMode by 113.5% during the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock worth $2,876,000 after acquiring an additional 90,173 shares during the last quarter. Meritage Portfolio Management lifted its holdings in InMode by 12.3% during the 4th quarter. Meritage Portfolio Management now owns 16,575 shares of the healthcare company's stock worth $277,000 after buying an additional 1,810 shares in the last quarter. Harvey Capital Management Inc. boosted its position in InMode by 1.4% in the 4th quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company's stock valued at $860,000 after buying an additional 700 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of InMode by 14.6% in the 4th quarter. Principal Financial Group Inc. now owns 99,562 shares of the healthcare company's stock valued at $1,663,000 after buying an additional 12,661 shares during the period. Finally, D.A. Davidson & CO. increased its stake in shares of InMode by 5.7% in the 4th quarter. D.A. Davidson & CO. now owns 43,651 shares of the healthcare company's stock valued at $729,000 after buying an additional 2,373 shares during the period. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

INMD has been the subject of a number of analyst reports. BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. Canaccord Genuity Group cut their target price on shares of InMode from $17.00 to $15.00 and set a "hold" rating on the stock in a report on Tuesday, April 29th. Needham & Company LLC reissued a "hold" rating on shares of InMode in a report on Monday, April 28th. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Finally, Robert W. Baird cut InMode from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $18.54.

InMode Trading Up 0.3%

Shares of InMode stock traded up $0.04 during trading on Wednesday, reaching $14.75. The stock had a trading volume of 84,669 shares, compared to its average volume of 1,183,595. The company has a market capitalization of $932.33 million, a price-to-earnings ratio of 6.28 and a beta of 2.02. The stock has a fifty day moving average price of $15.05 and a two-hundred day moving average price of $16.99. InMode Ltd. has a 52 week low of $13.68 and a 52 week high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.14). The business had revenue of $77.87 million for the quarter, compared to the consensus estimate of $82.21 million. InMode had a return on equity of 18.25% and a net margin of 45.91%. InMode's revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.32 earnings per share. On average, equities analysts forecast that InMode Ltd. will post 1.75 EPS for the current fiscal year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.